PASADENA, Calif. - Xencor, Inc. (NASDAQ:XNCR), a biopharmaceutical company specializing in engineered antibodies for the treatment of cancer and other serious diseases, announced today the pricing of its public offering. The company has priced 6,635,112 shares of common stock at $18.00 each and pre-funded warrants for 3,088,888 shares at $17.99 per warrant, with a nominal exercise price of $0.01 per share. The gross proceeds are expected to be around $175 million, excluding underwriting discounts, commissions, and other offering expenses.
The offering includes a 30-day option for underwriters to purchase up to an additional 1,458,600 shares. Leerink Partners, Raymond James, and RBC Capital Markets are the joint book-running managers, while Wedbush PacGrow is the co-manager.
The expected closing date of the offering is September 12, 2024, subject to customary conditions. Xencor has stated its intention to use the net proceeds for general corporate purposes, which may encompass research and development, capital expenditures, working capital, and administrative expenses.
This offering is pursuant to an automatic shelf registration statement filed with the Securities and Exchange Commission (the SEC) on February 27, 2023. The securities will be available through a prospectus and prospectus supplement forming part of the registration statement.
Xencor's portfolio includes more than 20 candidates in clinical development, and three of its XmAb-engineered medicines are marketed by partners. The company's technology allows for modifications to protein structures, resulting in new therapeutic mechanisms.
The information provided is based on a press release statement and does not constitute an offer to sell or a solicitation of an offer to buy in any jurisdiction where it would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
In other recent news, Xencor Inc . has initiated a public offering of its common stock, aiming to raise funds for general corporate purposes. The size and timing of the offering are subject to market conditions, with Leerink Partners, Raymond James, and RBC Capital Markets acting as joint book-running managers. Also, Xencor has reported positive clinical activity in its Phase 1 study of XmAb819, a treatment for advanced clear cell renal cell carcinoma, and plans to launch four clinical studies targeting autoimmune diseases.
Analysts' views on Xencor have been mixed. JPMorgan (NYSE:JPM) has maintained a bullish stance, citing the potential of Xencor's autoimmune strategy and new pipeline assets, while Barclays (LON:BARC) reaffirmed its underweight rating, awaiting further clinical data. BMO Capital Markets and TD Cowen have also maintained their positive ratings on Xencor, pointing to the company's strategic shift to prioritize new programs targeting rheumatoid arthritis and inflammatory bowel disease.
In addition, Xencor regained full rights to its cancer treatment drug, plamotamab, after Janssen Biotech, Inc.'s decision to terminate its involvement. The company also welcomed Bart Cornelissen as its new Senior Vice President and Chief Financial Officer. These represent some of the recent developments that highlight Xencor's ongoing evolution.
InvestingPro Insights
As Xencor, Inc. (NASDAQ:XNCR) moves forward with its public offering, a glance at the company's financial health and market performance provides valuable context for investors. Xencor's strategic financial position is highlighted by its ability to maintain more cash than debt on its balance sheet, an InvestingPro Tip that suggests a solid foundation for managing its capital and funding future growth. This is particularly reassuring as the company plans to channel the net proceeds from the offering into various corporate activities, including its extensive research and development efforts.
However, it's worth noting that analysts have tempered expectations, with six analysts revising their earnings projections downwards for the upcoming period, indicating potential concerns over the company's near-term profitability. In addition, the analysts anticipate a sales decline in the current year, which could be a factor for investors to consider when evaluating the company's growth trajectory.
From a market performance perspective, Xencor has experienced significant returns over the last week, with a 15.03% increase, and an even stronger return over the past month, at 19.26%. Yet, the company's gross profit margin presents a challenge, with recent data showing a margin of -84.4%, reflecting a substantial cost of goods sold relative to its revenue. This data point, coupled with the company's non-payment of dividends, may influence the investment strategies of income-focused shareholders.
Investors interested in a deeper dive into Xencor's financials and market performance can find additional InvestingPro Tips, including insights on profitability and liquidity, by visiting InvestingPro. With over ten tips available, InvestingPro offers a comprehensive analysis to help investors make informed decisions.
As Xencor embarks on its latest capital-raising venture, the insights from InvestingPro offer a nuanced view of the company's financial standing and market performance, both of which are crucial for investors to ponder in light of the public offering and the company's future endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.